July newsletter

Cell and gene therapies are different to traditional medicines and existing reimbursement practices do not easily accommodate the possible outstanding value that these potentially curative and disease-modifying therapies could deliver.

The Health Economics and Market Access Team at CGT Catapult have been looking at how outcomes-based reimbursement could support the adoption of these therapies. Outcomes-based reimbursement requires patient outcomes data to be collected, analysed and linked to payments; central to this is the availability of a suitable data collection and management infrastructure. 

In a series of case studies, the team describes opportunities and challenges with current data collection infrastructure and identifies approaches for its optimisation:
 

• Can the existing data collection infrastructures for patient outcomes enable outcomes-based reimbursement in the UK?
• To what extent can the European Society for Blood and Marrow Transplantation (EBMT) registry enable outcomes-based reimbursement in oncology in the UK?
• To what extent can the Systemic Anti-Cancer Therapy (SACT) database enable outcomes-based reimbursement in oncology in England?
• The appropriateness of the NHR for facilitating performance-based reimbursement in thalassaemia – current state and future perspectives
• Enabling outcomes-based reimbursement through a universal platform for outcomes data

Additionally, this recent paper published in the Journal of Market Access & Health Policy identifies the key requirements for upgrading the Systemic Anti-Cancer Therapy (SACT) database and European Society for Blood and Marrow Transplantation (EBMT) registry for the purposes of enabling outcomes-based reimbursement in oncology.

To see other peer-reviewed publications on reimbursement of cell and gene therapies please visit the CGT Catapult website.